A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Once known mainly for their role in weight management, GLP-1 receptor agonists, like semaglutide and tirzepatide, are now ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

Experts say people who take GLP-1 weight loss medications should stay hydrated, particularly when temperatures are high. The ...

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...